ClinicalTrials.gg
CompletedNCT02088073Updated Dec 7, 2018Results posted

Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

A Phase 3 interventional study of Sodium zirconium cyclosilicate and Placebo in Hyperkalemia, sponsored by ZS Pharma, Inc.. Completed at 46 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-07.

Sponsored by ZS Pharma, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.

Enrollment
7th of 27
258 · median 120
Started
2014
with 2 others
Phase 3
12 of 27
none open now
Registered
1st of 27
by date
Lead sponsor
3 of 27
ZS Pharma, Inc.

Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 7th largest by enrollment, is one of 3 that started in 2014, is one of 12 in phase 3, and was the 1st registered.

Hyperkalemia

134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.

Browse Hyperkalemia studies →

Open to participants now

3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sodium zirconium cyclosilicate

sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, or all of them as a file.
02

Study summary

It is hypothesized that ZS is more effective than placebo control (alternative hypothesis) in maintaining mean double-blind randomized maintenance phase (DBRMP) Day 8-29 serum potassium levels (3.5 - 5.0 mmol/l, inclusive) among hyperkalemic subjects in whom normokalemia was established during the open-label acute phase versus no difference between each ZS dose (highest to lowest) versus placebo control (null hypothesis).

Read the detailed description

Approximately 275 subjects with hyperkalemia (two consecutive i-STAT potassium levels ≥ 5.1 mmol/l, taken 60 minutes apart at baseline) will be enrolled in the Open-label Acute Phase to provide 232 subjects in the Double Blind Randomized Maintenance Phase.

Initially all subjects will receive open-label ZS at a dose of 10g three times a day (tid) for 48 hours (AP). Subjects who achieve normokalemia (i-STAT potassium values between 3.5 to 5.0 mmol/l, inclusive) on the morning of Study Day 3 (after 6 doses of 10g ZS) will then, in a double-blind fashion, be randomized 4:4:4:7 to receive one of three doses of ZS (5g, 10g or 15g) or placebo control, qd for the following 28 days (DBRMP).

Safety and tolerability will be assessed on an ongoing basis by an Independent Data Monitoring Committee (iDMC). Each active dose group in the DBRMP will consist of 49 subjects and the placebo control group will consist of 85 subjects for a total of 232 subjects to detect a 0.6 effect size difference between each ZS dose (from highest to lowest) and placebo control; the 4:4:4:7 allocation optimizes the multiple comparisons to the placebo control for the DBRMP.

03

Conditions studied

  • Hyperkalemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written .
  • Over 18 years of age.
  • Two consecutive i-STAT potassium values, measured 60-minutes apart, both ≥5.1 mmol/l and measured within 1 day of the first ZS dose on AP Study Day 1.
  • Ability to have repeated blood draws or effective venous catheterization.
  • Women of must be using two forms of medically acceptable (at least one barrier method) and have a negative pregnancy test at AP Study Day 1. Women who are surgically sterile or those who are for at least 2 years are not considered to be of childbearing potential.

Exclusion criteria

Exclusion Criteria:

  • Pseudohyperkalemia signs and symptoms, such as excessive fist clenching hemolyzed blood specimen, history of severe leukocytosis or thrombocytosis.
  • Subjects treated with lactulose, Xifaxan or other non-absorbed antibiotics for hyperammonemia within 7 days prior to the first dose of study drug.
  • Subjects treated with resins (such as sevelamer acetate or sodium polystyrene sulfonate [SPS; e.g. Kayexalate®]), calcium acetate, calcium carbonate, or lanthanum carbonate, within 7 days prior to the first dose of study drug.
  • Subjects with a of less than 3 months.
  • Subjects who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the subjects' tasks associated with the protocol.
  • Women who are pregnant, lactating, or planning to become pregnant.
  • Subjects with diabetic ketoacidosis.
  • Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.
  • Known or previous anaphylaxis to ZS or to components thereof.
  • Randomization into the previous ZS-002 or ZS-003 studies.
  • Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry.
  • Subjects with cardiac arrhythmias that require immediate treatment.
  • Subjects on dialysis.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    Sodium zirconium cyclosilicate 10 g three times daily

    Sodium zirconium cyclosilicate 10 g three times daily for 48 hours (acute phase)

    Drug: Sodium zirconium cyclosilicate

  • Placebo comparator
    Placebo once daily

    Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days.

    Drug: Placebo

  • Experimental
    Sodium zirconium cyclosilicate 5 g once daily

    Sodium zirconium cyclosilicate (ZS) 5 g once daily for 28 days (maintenance phase)

    Drug: Sodium zirconium cyclosilicate

  • Experimental
    Sodium zirconium cyclosilicate 10 g once daily

    Sodium zirconium cyclosilicate (ZS) 10 g once daily for 28 days (maintenance phase)

    Drug: Sodium zirconium cyclosilicate

  • Experimental
    Sodium zirconium cyclosilicate 15 g once daily

    Sodium zirconium cyclosilicate (ZS) 15 g once daily for 28 days (maintenance phase)

    Drug: Sodium zirconium cyclosilicate

Interventions

  • Sodium zirconium cyclosilicate

    Also known as: ZS; Microporous, Fractionated, Protonated Zirconium Silicate; Zirconium Silicate

  • DrugPlacebo

    Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)

    Also known as: Silicilate microcrystaline cellulose

06

What researchers measure

Primary outcomes

  1. Mean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population).

    The least squares means (LSMeans) are dervied from a mixed effects model of serial log transformed S-K values between Days 8 and 29 with patients as a random effect and the following fixed effects terms: MP treatment group; AP baseline eGFR; AP and MP baseline S-K levels, age categories (\<55, 55-64, \>= 65 years); and binary indicators for RAAS inhibitors use, CKD, CHF, and DM. The LSmeans estimate obtained from the above model is back-transformed and presented as the lsmeans of all available S-K values during the Maintenance phase study Days 8 to 29.

    Time frame: 22 Days; Maintenance Phase Days 8 - 29, inclusive.

Secondary outcomes

  1. The Number of Normokalemic Days Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT).

    The number of normokalemic days during the Maintenance Phase Study Days 8 to 29 is calculated assuming that the interval between assessments is normokalemic only if both the beginning and end assessments for that time interval display normal S-K values (i.e. 3.5 - 5.0 mmol/L)

    Time frame: 22 days; Maintenance Phase Day 8 - 29, inclusive.

  2. Mean Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit .

    Time frame: Acute Phase baseline to Maintenance Phase Study Day 2 to Day 29/Exit, inclusive.

  3. Mean Percent Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit, Inclusive .

    Time frame: Acute Phase baseline to Maintenance Phase Study Day 2 to Day 29/Exit, inclusive.

  4. Mean Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.

    Time frame: Maintenance phase baseline to Maintenance Phase Study Day 29/Exit, inclusive.

  5. Mean Percent Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.

    Time frame: Maintenance phase baseline to Maintenance Phase Study Day 29/Exit, inclusive.

  6. Median Time to Hyperkalemia (S-K ≥ 5.1mmol/L)

    Time frame: Maintenance Phase baseline to maintenance Phase Study Day 29/Exit.

  7. Mean S-K Intra-subject Standard Deviation Calculated Among Subjects With ≥ 2 Values on or After Maintenance Phase Study Day 8

    Time frame: 22 days; Maintenance Phase Day 8 - 29

  8. Proportion of Subjects Who Remained Normokalemic During Maintenance Phase

    Time frame: Maintenance Phase Study Days 1, 2, 5, 8, 12, 15, 19, 22, 26, 29, and 35, inclusive.

  9. Median Time to Relapse in S-K Values

    Median time to relapse in S-K values (return to original Acute Phase S-K baseline value)

    Time frame: Maintenance phase Study Day 1 to Study Day 29/Exit.

  10. Exponential Rate of Change in S-K Values During the Acute Phase at 24 Hours and 48 Hours of Study Drug Treatment.

    Time frame: Acute Phase 24 hours and Acute Phase 48 hours.

  11. Mean Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.

    Time frame: All measured time intervals post dose during the Acute Phase.

  12. Mean Percent Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.

    Time frame: All measured time intervals post dose during the Acute Phase.

  13. Proportion of Subjects Who Achieve Normokalemia During the Acute Phase at 24 and 48 Hours After Start of Dosing

    Time frame: Through 48 hours acute phase

  14. Median Time to Normalization (3.50-5.0 mmol/L) in S-K Levels in the 48 Hours of Initial Treatment

    Time frame: Through 48 hours acute phase

07

Results

Posted Dec 7, 2018

Participant flow

Participants took part in the study at 44 sites in the United States, Australia, and South Africa from 31 March 2014 to 08 August 2014

Acute Phase
Participant flow — Acute Phase
MilestoneZS 10 g Three Times Daily (Acute Phase)Placebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
Started2580000
Completed2510000
Not completed70000
Withdrew: Withdrawal by subject50000
Withdrew: Hyperkalemia20000
Maintanance Phase
Participant flow — Maintanance Phase
MilestoneZS 10 g Three Times Daily (Acute Phase)Placebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
Started085455156
Completed075404449
Not completed010577
Withdrew: Withdrawal by subject02000
Withdrew: Adverse event00301
Withdrew: Physician decision00001
Withdrew: Sponsor's decision02021
Withdrew: Hypo- or hyperkalemia03031
Withdrew: Miscellaneous02121
Withdrew: Met ecg withdrawal criteria00102
Withdrew: Subject compliance01000

Outcome measures

PrimaryMean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population).

The least squares means (LSMeans) are dervied from a mixed effects model of serial log transformed S-K values between Days 8 and 29 with patients as a random effect and the following fixed effects terms: MP treatment group; AP baseline eGFR; AP and MP baseline S-K levels, age categories (\<55, 55-64, \>= 65 years); and binary indicators for RAAS inhibitors use, CKD, CHF, and DM. The LSmeans estimate obtained from the above model is back-transformed and presented as the lsmeans of all available S-K values during the Maintenance phase study Days 8 to 29.

Time frame:
22 Days; Maintenance Phase Days 8 - 29, inclusive.
Reported as:
Least squares mean · mmol/L
Mean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population).
mmol/LPlacebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
Mean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population).5.0603 (4.9646 to 5.1578)4.7544 (4.6350 to 4.8769)4.5081 (4.4005 to 4.6184)4.3742 (4.2754 to 4.4753)
SecondaryThe Number of Normokalemic Days Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT).

The number of normokalemic days during the Maintenance Phase Study Days 8 to 29 is calculated assuming that the interval between assessments is normokalemic only if both the beginning and end assessments for that time interval display normal S-K values (i.e. 3.5 - 5.0 mmol/L)

Time frame:
22 days; Maintenance Phase Day 8 - 29, inclusive.
Reported as:
Mean · Days
The Number of Normokalemic Days Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT).
DaysPlacebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
The Number of Normokalemic Days Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT).7.4 ± 8.013.4 ± 7.5713.9 ± 7.9116.8 ± 6.99
SecondaryMean Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit .
Time frame:
Acute Phase baseline to Maintenance Phase Study Day 2 to Day 29/Exit, inclusive.
Reported as:
Mean · mmol/L
Mean Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit .
mmol/LPlacebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
AP Baseline S-K level5.55 ± 0.4715.53 ± 0.3575.58 ± 0.4235.55 ± 0.331
MP Study Day 2 Mean Change-0.86 ± 0.508-1.03 ± 0.408-1.25 ± 0.471-1.12 ± 0.477
MP Study Day 8 Mean Change-0.49 ± 0.549-0.72 ± 0.552-1.09 ± 0.629-1.20 ± 0.592
MP Study Day 12 Mean Change-0.41 ± 0.508-0.75 ± 0.516-1.11 ± 0.663-1.20 ± 0.665
MP Study Day 15 Mean Change-0.48 ± 0.612-0.77 ± 0.492-1.11 ± 0.652-1.19 ± 0.627
MP Study Day 19 Mean Change-0.45 ± 0.549-0.79 ± 0.520-1.04 ± 0.581-1.07 ± 0.575
MP Study Day 22 Mean Change-0.45 ± 0.578-0.71 ± 0.543-0.93 ± 0.653-1.05 ± 0.586
MP Study Day 26 Mean Change-0.43 ± 0.552-0.65 ± 0.448-0.87 ± 0.697-1.03 ± 0.597
MP Study Day 29 Mean Change-0.47 ± 0.499-0.69 ± 0.500-1.08 ± 0.704-1.12 ± 0.571
MP Study Day 29/Exit Mean Change-0.44 ± 0.515-0.77 ± 0.559-1.10 ± 0.813-1.19 ± 0.659
SecondaryMean Percent Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit, Inclusive .
Time frame:
Acute Phase baseline to Maintenance Phase Study Day 2 to Day 29/Exit, inclusive.
Reported as:
Mean · Percent Change
Mean Percent Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit, Inclusive .
Percent ChangePlacebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
MP Study Day 2 Percent Change-15.11 ± 8.154-18.53 ± 6.941-22.19 ± 7.897-20.04 ± 7.959
MP Study Day 8 Percent Change-8.45 ± 9.492-12.84 ± 9.700-19.16 ± 10.708-21.29 ± 10.135
MP Study Day 12 Percent Change-7.22 ± 8.967-13.36 ± 8.949-19.45 ± 11.072-21.22 ± 11.368
MP Study Day 15 Percent Change-8.28 ± 10.739-13.73 ± 8.485-19.33 ± 10.884-21.19 ± 10.675
MP Study Day 19 Percent Change-7.87 ± 9.554-14.08 ± 8.822-18.29 ± 9.707-19.10 ± 9.957
MP Study Day 22 Percent Change-7.74 ± 9.992-12.65 ± 9.591-16.25 ± 11.292-18.65 ± 10.034
MP Study Day 26 Percent Change-7.54 ± 9.386-11.83 ± 8.025-15.18 ± 11.988-18.28 ± 10.271
MP Study Day 29 Percent Change-8.23 ± 8.586-12.49 ± 8.770-18.83 ± 11.951-19.80 ± 9.503
MP Study Day 29/Exit Percent Change-7.68 ± 8.940-13.85 ± 9.568-19.28 ± 14.099-21.06 ± 11.086
SecondaryMean Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.
Time frame:
Maintenance phase baseline to Maintenance Phase Study Day 29/Exit, inclusive.
Reported as:
Mean · mmol/L
Mean Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.
mmol/LPlacebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
MP Baseline S-K level4.55 ± 0.4274.51 ± 0.3574.38 ± 0.4074.45 ± 0.372
MP Study Day 2 Mean change0.13 ± 0.411-0.01 ± 0.372-0.04 ± 0.384-0.02 ± 0.400
MP Study Day 8 Mean change0.50 ± 0.5380.30 ± 0.4670.12 ± 0.523-0.10 ± 0.535
MP Study Day 12 Mean change0.60 ± 0.5800.26 ± 0.5410.10 ± 0.594-0.11 ± 0.572
MP Study Day 15 Mean change0.54 ± 0.6940.25 ± 0.5350.11 ± 0.552-0.10 ± 0.546
MP Study Day 19 Mean change0.55 ± 0.6720.22 ± 0.5800.17 ± 0.4830.01 ± 0.605
MP Study Day 22 Mean change0.55 ± 0.6270.30 ± 0.5630.27 ± 0.6500.03 ± 0.579
MP Study Day 26 Mean change0.55 ± 0.6230.34 ± 0.5650.33 ± 0.6730.05 ± 0.594
MP Study Day 29 Mean change0.52 ± 0.5450.28 ± 0.6640.14 ± 0.668-0.04 ± 0.554
MP Study Day 29/Exit Mean change0.56 ± 0.5820.25 ± 0.6450.11 ± 0.768-0.09 ± 0.598
SecondaryMean Percent Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.
Time frame:
Maintenance phase baseline to Maintenance Phase Study Day 29/Exit, inclusive.
Reported as:
Mean · Percent Change
Mean Percent Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.
Percent ChangePlacebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
MP Study Day 2 Percent change3.39 ± 9.0440.06 ± 8.036-0.51 ± 8.862-0.20 ± 8.984
MP Study Day 8 Percent change11.64 ± 12.2916.93 ± 10.4863.05 ± 12.346-1.74 ± 12.043
MP Study Day 12 Percent change13.70 ± 13.0726.38 ± 12.2872.85 ± 13.595-2.00 ± 12.836
MP Study Day 15 Percent change12.51 ± 15.6935.95 ± 12.1692.93 ± 12.662-1.89 ± 12.118
MP Study Day 19 Percent change12.96 ± 15.7915.33 ± 12.9344.28 ± 11.231.095 ± 13.697
MP Study Day 22 Percent change12.84 ± 14.3426.98 ± 12.7746.79 ± 15.1741.39 ± 12.782
MP Study Day 26 Percent change13.03 ± 14.5667.98 ± 12.9328.08 ± 15.5161.88 ± 16.641
MP Study Day 29 Percent change12.09 ± 13.1166.12 ± 14.4243.02 ± 17.785-1.43 ± 13.664
MP Study Day 29/Exit Percent change12.97 ± 13.1166.12 ± 14.4243.02 ± 17.785-1.43 ± 13.664
SecondaryMedian Time to Hyperkalemia (S-K ≥ 5.1mmol/L)
Time frame:
Maintenance Phase baseline to maintenance Phase Study Day 29/Exit.
Reported as:
Median · Days
Median Time to Hyperkalemia (S-K ≥ 5.1mmol/L)
DaysPlacebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
Median Time to Hyperkalemia (S-K ≥ 5.1mmol/L)7 (6 to 7)14 (7 to 28)NA (NA to NA)NA (NA to NA)
SecondaryMean S-K Intra-subject Standard Deviation Calculated Among Subjects With ≥ 2 Values on or After Maintenance Phase Study Day 8
Time frame:
22 days; Maintenance Phase Day 8 - 29
Reported as:
Mean · mmol/L
Mean S-K Intra-subject Standard Deviation Calculated Among Subjects With ≥ 2 Values on or After Maintenance Phase Study Day 8
mmol/LPlacebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
Mean S-K Intra-subject Standard Deviation Calculated Among Subjects With ≥ 2 Values on or After Maintenance Phase Study Day 80.06392 (0.05804 to 0.06980)0.06367 (0.05574 to 0.07159)0.07708 (0.06941 to 0.08474)0.06849 (0.06126 to 0.07571)
SecondaryProportion of Subjects Who Remained Normokalemic During Maintenance Phase
Time frame:
Maintenance Phase Study Days 1, 2, 5, 8, 12, 15, 19, 22, 26, 29, and 35, inclusive.
Reported as:
Number · Proportion of subjects
Proportion of Subjects Who Remained Normokalemic During Maintenance Phase
Proportion of subjectsPlacebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
Baseline0.8660.9330.9200.926
MP Study Day 20.840.9330.9180.944
MP Study Day 80.4810.7110.8200.852
MP Study Day 120.4000.7500.7870.849
MP Study Day 150.4380.7050.8510.827
MP Study Day 190.4490.7440.7870.882
MP Study Day 220.4420.6740.6670.882
MP Study Day 260.4860.7380.7110.843
MP Study Day 290.5070.6670.8160.907
MP Study Day 29/Exit0.4760.7110.7600.852
SecondaryMedian Time to Relapse in S-K Values

Median time to relapse in S-K values (return to original Acute Phase S-K baseline value)

Time frame:
Maintenance phase Study Day 1 to Study Day 29/Exit.
Reported as:
Median · Days
Median Time to Relapse in S-K Values
DaysPlacebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
Median Time to Relapse in S-K Values19 (12 to 28)29 (29 to NA)NA (NA to NA)NA (NA to NA)
SecondaryExponential Rate of Change in S-K Values During the Acute Phase at 24 Hours and 48 Hours of Study Drug Treatment.
Time frame:
Acute Phase 24 hours and Acute Phase 48 hours.
Reported as:
Mean · log(mmol/L/hour)
Exponential Rate of Change in S-K Values During the Acute Phase at 24 Hours and 48 Hours of Study Drug Treatment.
log(mmol/L/hour)Acute Phase: ZS 10 g TID
24 hours after start of ZS dosing-0.00373 ± 0.000231
48 hours of start of ZS dosing-0.00324 ± 0.000130
SecondaryMean Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.
Time frame:
All measured time intervals post dose during the Acute Phase.
Reported as:
Mean · mmol/L
Mean Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.
mmol/LAcute Phase: ZS 10 g TID
Acute phase baseline5.55 ± 0.449
1 hour after start of ZS dosing Mean change-0.23 ± 0.435
2 hours after start of ZS dosing Mean change-0.41 ± 0.440
4 hours after start of ZS dosing Mean change-0.51 ± 0.405
24 hours after start of ZS dosing Mean change-0.68 ± 0.448
1 hour after 1st dose Study Day 2 Mean change-0.75 ± 0.444
48 hours after start of ZS dosing Mean change-1.05 ± 0.510
SecondaryMean Percent Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.
Time frame:
All measured time intervals post dose during the Acute Phase.
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.
Percent ChangeAcute Phase: ZS 10 g TID
1 hour after start of ZS dosing Percent change-3.91 ± 7.741
2 hours after start of ZS dosing Percent change-7.13 ± 7.706
4 hours after start of ZS dosing Percent change-9.00 ± 7.123
24 hours after start of ZS dosing Percent change-12.03 ± 7.808
1 hour after 1st dose Study Day 2 Percent change-13.41 ± 7.720
48 hours after start of ZS dosing Percent change-18.56 ± 8.506
SecondaryProportion of Subjects Who Achieve Normokalemia During the Acute Phase at 24 and 48 Hours After Start of Dosing
Time frame:
Through 48 hours acute phase
Reported as:
Number · Proportion of subjects
Proportion of Subjects Who Achieve Normokalemia During the Acute Phase at 24 and 48 Hours After Start of Dosing
Proportion of subjectsAcute Phase: ZS 10 g TID
24 hours after start of dosing0.661
48 hours after of start dosing0.88
SecondaryMedian Time to Normalization (3.50-5.0 mmol/L) in S-K Levels in the 48 Hours of Initial Treatment
Time frame:
Through 48 hours acute phase
Reported as:
Median · Hours
Median Time to Normalization (3.50-5.0 mmol/L) in S-K Levels in the 48 Hours of Initial Treatment
HoursAcute Phase: ZS 10 g TID
Median Time to Normalization (3.50-5.0 mmol/L) in S-K Levels in the 48 Hours of Initial Treatment2.17 (2 to 3.97)

Adverse events

Collected over All adverse events were collected beginning with the first administration of study drug and through end of study treatment follow up visit. End of treatment study follow up visit was 7 days +/- 1 day after last dose of investigational product.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZS 10 g TID (Acute Phase)—0/258 (0%)9/258 (3.5%)
Placebo Comparator (Maintenance Phase)—0/85 (0%)25/85 (29.4%)
ZS 5 g Once Daily (Maintenance Phase)—5/45 (11.1%)20/45 (44.4%)
ZS 10 g Once Daily (Maintenance Phase)—2/51 (3.9%)15/51 (29.4%)
ZS 15 g Once Daily (Maintenance Phase)—3/56 (5.4%)25/56 (44.6%)
Most frequent serious events
Most frequent serious events
EventZS 10 g TID (Acute Phase)Placebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
Cardiac failure congestiveCardiac disorders0/2580/851/450/510/56
Small intestinal obstructionGastrointestinal disorders0/2580/851/450/510/56
HepatotoxicityHepatobiliary disorders0/2580/851/450/510/56
PneumoniaInfections and infestations0/2580/851/450/511/56
Confusional statePsychiatric disorders0/2580/851/450/510/56
Myocardial infarctionCardiac disorders0/2580/850/451/510/56
CellulitisInfections and infestations0/2580/850/451/510/56
Generalized edemaGeneral disorders0/2580/850/450/511/56
DyspnoeaRespiratory, thoracic and mediastinal disorders0/2580/850/450/511/56
Most frequent other events
Showing 10 of 29
Most frequent other events
EventZS 10 g TID (Acute Phase)Placebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)
EdemaGeneral disorders0/2582/851/453/518/56
FatigueGeneral disorders0/2580/850/455/516/56
Oedema peripheralGeneral disorders0/2582/850/453/516/56
ConstipationGastrointestinal disorders2/2586/850/451/511/56
Upper respiratory infectionInfections and infestations1/2581/853/451/511/56
AnemiaBlood and lymphatic system disorders0/2580/850/450/513/56
NasopharyngitisInfections and infestations0/2581/850/450/513/56
DyspepsiaGastrointestinal disorders0/2580/852/450/510/56
HypertensionVascular disorders0/2581/852/451/512/56
Renal failureRenal and urinary disorders0/2580/852/450/510/56

Baseline characteristics

Some participants contributed to more than one baseline group. 258 participants entered the acute phase; 251 completed the acute phase. Of these 251 participants, 240 were eligible for the maintenance phase. Three participants did not enter the maintenance phase; 237 participants were randomized for the maintenance phase.

Age, Continuous
Age, Continuous(Years)ZS 10 g Three Times Daily (Acute Phase)Placebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)Total
Acute Phase64.0 ± 12.72NA ± NANA ± NANA ± NANA ± NA64.0 ± 12.72
Maintenance PhaseNA ± NA64.3 ± 12.1361.5 ± 16.8963.8 ± 9.9764.9 ± 12.8563.80 ± 13.01
Sex/Gender, Customized
Sex/Gender, Customized(Participants)ZS 10 g Three Times Daily (Acute Phase)Placebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)Total
Female, Acute Phase1090000109
Male, Acute Phase1490000149
Female, Maintenance Phase04118241699
Male, Maintenance Phase044272740138
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ZS 10 g Three Times Daily (Acute Phase)Placebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)Total
White, Acute Phase2150000215
Black or African American, Acute Phase37000037
Asian, Acute Phase500005
Native Hawaiian or other Pacific Islander, AP100001
Other, Acute Phase200002
Multiple Races indicated, Acute Phase100001
White, Maintenance Phase073364446199
Black or African American, Maintenance Phase01085932
Asian, Maintenance Phase030115
Native Hawaiian or other Pacific Islander, MP010001
Other, Maintenance Phase001102
Multiple Races indicated, Maintenance Phase010001
Baseline Serum potassium ( S-K ) levels during both the Acute and Maintenance phases
Baseline Serum potassium ( S-K ) levels during both the Acute and Maintenance phases(Participants)ZS 10 g Three Times Daily (Acute Phase)Placebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)Total
<5.5 mmol/L, Acute Phase1190000119
5.5-<6.0 mmol/L, Acute Phase1000000100
≥ 6.0 mmol/L, Acute Phase39000039
<5.5 mmol/L, Maintenance Phase043231924109
5.5-<6.0 mmol/L, Maintenance Phase03017232696
≥ 6.0 mmol/L, Maintenance Phase01259632
eGFR at baseline during both the Acute and Maintenance phases
eGFR at baseline during both the Acute and Maintenance phases(Participants)ZS 10 g Three Times Daily (Acute Phase)Placebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)Total
<60 mL/min, Acute Phase1790000179
≥ 60 mL/min, Acute Phase72000072
Not reported, Acute Phase700007
<60 mL/min, Maintenance Phase052313841162
≥ 60 mL/min, Maintenance Phase02812131568
Not reported, Maintenance Phase052007
Etiology of elevated S-K levels during both the Acute and Maintenance phases
Etiology of elevated S-K levels during both the Acute and Maintenance phases(Participants)ZS 10 g Three Times Daily (Acute Phase)Placebo Comparator (Maintenance Phase)ZS 5 g Once Daily (Maintenance Phase)ZS 10 g Once Daily (Maintenance Phase)ZS 15 g Once Daily (Maintenance Phase)Total
RAAS inhibitor medication, Acute Phase1800000180
Diabetes mellitus, Acute Phase1700000170
Chronic kidney disease, Acute Phase1690000169
Heart failure, Acute Phase94000094
RAAS inhibitor medication, Maintenance Phase061333633163
Diabetes mellitus, Maintenance Phase054263839157
Chronic kidney disease, Maintenance Phase050293637152
Heart failure, Maintenance Phase02618182587
08

Study locations

46 sites
  • Anniston, Alabama, United States
  • Huntsville, Alabama, United States
  • Scottsboro, Alabama, United States
  • Phoenix, Arizona, United States
  • Tempe, Arizona, United States
  • Hawaiian Gardens, California, United States
  • Los Angeles, California, United States
  • Paramount, California, United States
  • Riverside, California, United States
  • Atlantis, Florida, United States
  • Bradenton, Florida, United States
  • Brandon, Florida, United States
  • Brooksville, Florida, United States
  • DeLand, Florida, United States
  • Edgewater, Florida, United States
  • Miami Lakes, Florida, United States
  • Miami, Florida, United States
  • New Smyrna Beach, Florida, United States
  • Ocala, Florida, United States
  • Summerfield, Florida, United States
  • Tampa, Florida, United States
  • Winter Park, Florida, United States
  • Columbus, Georgia, United States
  • Decatur, Georgia, United States
  • Evergreen Park, Illinois, United States
  • Joliet, Illinois, United States
  • Shreveport, Louisiana, United States
  • Auburn, Maine, United States
  • Chesterfield, Michigan, United States
  • Kansas City, Missouri, United States
  • Las Vegas, Nevada, United States
  • Flushing, New York, United States
  • Altoona, Pennsylvania, United States
  • Providence, Rhode Island, United States
  • Orangeburg, South Carolina, United States
  • Sumter, South Carolina, United States
  • Chattanooga, Tennessee, United States
  • San Antonio, Texas, United States
  • Gosford, New South Wales, Australia
  • Woolloongabba, Queensland, Australia
  • Heidelberg, Victoria, Australia
  • Melbourne, Victoria, Australia
  • Parkville, Victoria, Australia
  • Meyerspark, South Africa
  • Port Elizabeth, South Africa
  • Somerset West, South Africa
09

References and documents

Publications

  • Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020 Jun 26;6(6):CD013165. doi: 10.1002/14651858.CD013165.pub2. PubMed 32588430 ↗
  • Amin AN, Menoyo J, Singh B, Kim CS. Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level >/= 5.5 mmol/L: pooled analysis from two phase 3 trials. BMC Nephrol. 2019 Dec 2;20(1):440. doi: 10.1186/s12882-019-1611-8. PubMed 31791288 ↗
  • Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014 Dec 3;312(21):2223-33. doi: 10.1001/jama.2014.15688. Erratum In: JAMA. 2015 Feb 3;313(5):526. Dosage error in text. PubMed 25402495 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Aug 2014, 5 months.

Results were first posted in Dec 2018, 4 years 3 months after primary completion. A results delay was requested in Aug 2014.

Of 18 phase 3 interventional studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2014
First posted
Mar 14, 2014
StartActual
Mar 31, 2014
Primary completionActual
Aug 31, 2014
CompletionActual
Jan 31, 2015
Results delay requested
Aug 26, 2014
Results first posted
Dec 7, 2018
Last update
Dec 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02088073
Lead sponsor
ZS Pharma, Inc.
Responsible party
Sponsor
First posted
Mar 14, 2014
Start date
Mar 31, 2014
Primary completion
Aug 31, 2014
Completion
Jan 31, 2015
Results posted
Dec 7, 2018
Last update
Dec 7, 2018

Study contacts

Henrik Rasmussen, MD, PhD
study chair · ZS Pharma, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium zirconium cyclosilicate

Start the discussion